Eli Lilly: Developing Cymbalta - Case - Harvard Business School
Anticipating the expiration of its Prozac patent, Eli Lilly has to make tough decisions regarding the development of its next-generation antidepressant drug.
Eli Lilly: Developing Cymbalta - Harvard Business Publishing …
Nov 27, 2006 · Anticipating the expiration of its Prozac patent, Eli Lilly has to make tough decisions regarding the development of its next-generation antidepressant drug.
Eli Lilly: Developing Cymbalta
Nov 27, 2006 · Anticipating the expiration of its Prozac patent, Eli Lilly has to make tough decisions regarding the development of its next-generation antidepressant drug.
Lilly Launches New Antidepressant Cymbalta - Eli Lilly and …
Aug 24, 2004 · More than half of the nation's pharmacies, including drug store chains and independents, have stocked Cymbalta and can begin filling prescriptions immediately. Lilly expects more than 80 percent of pharmacies - more than 44,000 stores - to have Cymbalta on their shelves by Aug. 30.
Eli Lilly: Developing Cymbalta (TN) - Teaching Note - Faculty ...
Ofek, Elie. "Eli Lilly: Developing Cymbalta (TN)." Harvard Business School Teaching Note 508-061, December 2007. (Revised January 2008.)
Life Span of a Popular Antidepressant | Scientific American
Sep 1, 2013 · Cymbalta goes off patent at the end of the year. In July, Eli Lilly is expected to lay off up to 1,000 sales workers in anticipation of the revenue loss.
Eli Lilly: Developing Cymbalta - The Case Centre
Jul 30, 2008 · Anticipating the expiration of its Prozac patent, Eli Lilly has to make tough decisions regarding the development of its next-generation antidepressant drug.
CYMBALTA® is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of the following conditions: • Major depressive disorder (MDD) in adults (1)
Cymbalta is approved in the United States for the treatment of major depressive disorder, the management of diabetic peripheral neuropathic pain and now the treatment of generalized anxiety disorder, all in adults.
FDA Approves Cymbalta® for the Management of ... - Eli Lilly …
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations.
- Some results have been removed